20240016859. MICROENCAPSULATED AND CHROMOSOME INTEGRATED COMPOSITIONS FOR L-DOPA MICROBIOME THERAPY simplified abstract (Iowa State University Research Foundation, Inc.)
MICROENCAPSULATED AND CHROMOSOME INTEGRATED COMPOSITIONS FOR L-DOPA MICROBIOME THERAPY
Organization Name
Iowa State University Research Foundation, Inc.
Inventor(s)
Anumantha G. Kanthasamy of Ames IA (US)
Gregory Phillips of Ames IA (US)
Nicholas John Backes of Ames IA (US)
MICROENCAPSULATED AND CHROMOSOME INTEGRATED COMPOSITIONS FOR L-DOPA MICROBIOME THERAPY - A simplified explanation of the abstract
This abstract first appeared for US patent application 20240016859 titled 'MICROENCAPSULATED AND CHROMOSOME INTEGRATED COMPOSITIONS FOR L-DOPA MICROBIOME THERAPY
Simplified Explanation
The present invention is about methods and compositions for treating Parkinson's disease, Alzheimer's disease, depression, anxiety, and memory deficits. It involves the use of recombinant microorganisms, specifically gut-colonizing probiotics, that have been modified to produce l-dopa. The invention also includes microcapsules and lyophilized formulations containing these modified microorganisms.
- The invention focuses on the treatment of neurological disorders such as Parkinson's disease, Alzheimer's disease, depression, anxiety, and memory deficits.
- It involves the use of recombinant microorganisms, particularly gut-colonizing probiotics, that have been genetically modified to produce l-dopa.
- The invention also includes microcapsules and lyophilized formulations that contain these modified microorganisms.
- The production of l-dopa by the modified microorganisms offers a potential therapeutic approach for these neurological disorders.
- The microcapsules and lyophilized formulations provide convenient and stable delivery systems for the modified microorganisms.
Potential Applications
- Treatment of Parkinson's disease
- Treatment of Alzheimer's disease
- Treatment of depression
- Treatment of anxiety
- Treatment of memory deficits
Problems Solved
- Lack of effective treatments for Parkinson's disease, Alzheimer's disease, depression, anxiety, and memory deficits
- Limited availability of l-dopa, a key therapeutic agent for Parkinson's disease
- Challenges in delivering therapeutic agents to the gut for neurological disorders
Benefits
- Novel therapeutic approach using genetically modified microorganisms
- Potential for targeted delivery to the gut, where the modified microorganisms can colonize and produce l-dopa
- Microcapsules and lyophilized formulations provide convenient and stable delivery systems for the modified microorganisms
Original Abstract Submitted
the present invention generally provides methods and compositions for the treatment of parkinson's disease, alzheimer's disease, depression, anxiety, and memory deficits. the invention relates to recombinant microorganisms, particularly gut-colonizing probiotics, modified to produce l-dopa as well as microcapsules and lyophilized formulations comprising the same.
